Misplaced Pages

#443556

26-547: The Novozymes Prize is sponsored by the Novo Nordisk Foundation , and acknowledges exceptional European research or technological achievements that contribute to the advancement of innovative and sustainable solutions in biotechnology, benefiting both humanity and the environment. The name originates from the Danish biotechnology company Novozymes , specialising in enzyme production. The foundation, associated with Novozymes,

52-471: A concerning trend leading to excessive competition, reduced diversity, and the selection of conservative topics. There is a focus on evaluating potential imbalances in the distribution of research funds in Danish society regarding the role of the Novo Nordisk Foundation in advancing scientific research and innovation. One criticism is related to the foundation's significant economic influence in

78-463: A global leader in biotechnological solutions and enzyme production, promotes initiatives that drive progress in science and sustainability. The prize is awarded to individuals or research groups whose work has demonstrated significant impact and innovation in areas such as enzyme technology, industrial biotechnology , and sustainable solutions. Recipients of the Novozymes Prize are selected through

104-767: A little over 420 million US dollars to the Capital Region of Denmark to establish Steno Diabetes Center in Copenhagen , a diabetes treatment and research institution. The Novo Nordisk Foundation is an established enterprise foundation . It is a self-governing entity with no owners, focusing on long-term ownership of the Novo Group ( Novo Nordisk and Novozymes ) while combining business and philanthropy with scientific, humanitarian and social purposes. The Novo Nordisk Foundation's investment activities are managed by its 100%-owned subsidiary, Novo Holdings A/S whose sole purpose

130-542: A nomination and evaluation process by a committee composed of experts in relevant scientific disciplines . The Novozymes Prize consists of a monetary award and a commemorative medal. The recipient(s) are invited to deliver a lecture or presentation on their research during a ceremony held in conjunction with the award announcement. List of recipients of the Novozymes prize over the years: Official website Novo Nordisk Foundation The Novo Nordisk Foundation

156-531: Is a list of significant research initiatives: The Foundation has allocated $ 260 million to develop vaccines for respiratory diseases such as tuberculosis and influenza . This initiative, known as the Novo Nordisk Foundation Initiative for Vaccines and Immunity (NIVI), collaborates with the University of Copenhagen and Denmark's Statens Serum Institut . It emphasises generating immunity in

182-417: Is an international enterprise foundation focusing on medical treatment and research. In 2023, the foundation had a net worth of $ 167 billion (1,114 billion DKK), making it the wealthiest charitable foundation in the world . Novo Nordisk Foundation owns Novo Holdings A/S , a holding company that is the majority voting shareholder of Novo Nordisk , a Danish pharmaceutical corporation. From 2016 to 2022,

208-482: Is centered on the prevention and treatment of obesity , type 2 diabetes , and cardiovascular diseases , which are among the leading causes of death globally. The Foundation supports research in sustainable agriculture and food production techniques, aiming to address the challenge of sustainably feeding a growing global population. The initiative to create a world-class life sciences ecosystem in Denmark encompasses

234-407: Is designed to mitigate biases and increase the diversity of funded research, aiming to support high-quality, innovative projects that might otherwise be overlooked. The effectiveness of this strategy is being evaluated over a three-year trial period. The Novo Nordisk Foundation has been involved in numerous research initiatives, each focusing on areas of health and sustainability. Among others, below

260-524: Is to give company insiders a greater degree of power over the company and to provide a better defense against events like hostile takeover attempts. Class A share is also a way of pricing sales charges (loads) on mutual funds in the United States . In a class A share, the sales load is up front, typically at most 5.75% of the amount invested. In contrast is the class B share that does not have an upfront charge, but instead has higher ongoing expenses in

286-532: Is to invest the foundations wealth and ensure financial returns. Novo Holdings A/S is also the holding company for the foundation's ownership in Novo Group ( Novo Nordisk and Novozymes ). The Novo Nordisk Foundation is obligated to maintain its controlling ownership in the Novo Groups two largest companies: Novo Nordisk and Novozymes . The class A-shares in both companies (Novo Nordisk and Novozymes) are unlisted and cannot be traded . The voting weight of

SECTION 10

#1732898413444

312-437: Is working on developing vaccines and treatments for tuberculosis , addressing the broader issue of antimicrobial resistance . This initiative aims to combat a significant and growing global health threat. The Foundation's investment in stem cell-based therapy research focuses on new therapeutic approaches for chronic diseases , exploring the regenerative potential of stem cells . The Foundation's research in this area

338-477: The A-shares are 10 times those of B-shares in both companies. The Novo Nordisk Foundation receives cashflows and profits from paid dividends from Novo Holdings A/S . The paid dividends are taxed in the underlying companies in correspondence with Danish corporate tax laws, prior to being paid out as dividends. The Novo Nordisk Foundation is the primary owner of Novo Nordisk A/S and Novozymes A/S through

364-718: The Steno Diabetes Center research hospital. In addition, the Novo Nordisk Foundation also awards a number of awards each year aiming to recognize and reward individuals for "outstanding research, teaching, or other support for research". The Novo Nordisk Foundation awards several prestigious prizes, including the Novo Nordisk Prize for outstanding research in medical science and the Novozymes Prize focusing on biotechnology and environmental research. The foundation also recognise achievements in teaching and education in

390-518: The Nordic countries. This sparked the development of new diabetes treatments and the beginning of a Danish business and export venture. Several foundations were also established which have subsequently merged into the Novo Nordisk Foundation. In recent years, the Foundation has increased its focus on innovation, diabetes treatment and grants for humanitarian and social purposes. In 2016 the Foundation awarded

416-514: The Novo Nordisk Foundation is Lars Rebien Sørensen (former CEO of Novo Nordisk ) and Mads Krogsgaard Thomsen is the current CEO of the Novo Nordisk Foundation. Class A share In finance , a class A share refers to a share classification of common or preferred stock that typically has enhanced benefits with respect to dividends , asset sales, or voting rights compared to Class B or Class C shares . There may be restrictions on any specific issue of class A shares in exchange for

442-464: The airway, a novel approach in vaccine development. This initiative, formed in partnership with the Bill & Melinda Gates Foundation and Open Philanthropy , is focused on developing accessible oral antiviral treatments for viruses with pandemic potential. The initiative aims to support researchers globally in identifying and developing phase 2 -ready antiviral drug candidates. The Foundation

468-460: The benefits; for example, preferences with regard to dividends may be traded for reduced voting rights. They are often convertible into class B (may not be publicly traded ) shares at a favorable rate. For example, a company might allocate class A shares to its management giving them 7 times face value of class B shares, while class B shares have the same voting right as class A shares. Companies classify stock for many reasons. In some cases this

494-477: The concentration of its research funding, often favouring a select group of established researchers. This trend, prevalent in many countries, leads to funding disparities, where a majority of resources are allocated to a small percentage of researchers, often to the detriment of early-career, female, and diverse researchers. In response to these concerns, the Novo Nordisk Foundation has introduced partial randomisation in its grant allocation process. This new approach

520-603: The development of new research talent and established researchers. The initiative to support research infrastructure development aims to facilitate the creation and scaling up of innovative solutions and products, enhancing the capacity for scientific research and development . The Novo Nordisk Foundation contributed to support the fight against the COVID-19 pandemic in the spring of 2020. The foundation (as of June 2020) has donated DKK 366.2 million (approx $ 55.77 million) for COVID-19 related measures. The current chairman of

546-436: The entire value chain from basic research to scientific application, aiming to foster innovation and scientific breakthroughs. The Foundation's initiatives involve large-scale projects that encompass collaborations across various sectors and disciplines, focusing on addressing global challenges through international cooperation and partnership. The Foundation places a strong emphasis on natural science education, supporting

SECTION 20

#1732898413444

572-562: The foundation distributed more than US$ 4.5 billion in grants for research, innovation, treatment, education, humanitarian and social purposes. In 2023, the foundation awarded grants worth 9.1 billion DKK (approx. $ 1.33 billion) and paid out 5.8 billion DKK (approx. $ 0.84 billion). While the main focus lies within biomedicine and biotechnology research, the Foundation also awards grants for research in general practice and family medicine, nursing and art history. In 1922, Danish professor August Krogh received permission to produce insulin in

598-694: The foundation's subsidiary company Novo Holdings A/S . Aside from Novo Nordisk and Novozymes , the foundation is also a major shareholder in more than 135 other companies as of 2022. The foundation's financial endowment is maintained by dividends and returns on these investments. The Novo Nordisk Foundation offers various types of grants, categorised under five main models: The foundation has an objective of providing support for scientific, humanitarian and social purposes. The grants go primarily to support research in biomedicine , biotechnology , general medicine, nursing and art history at public knowledge institutions. Humanitarian and social purposes includes

624-498: The potential to contribute to overall societal well-being. Concerns have been raised about the potential influence of the foundation's agenda on the direction of scientific research. Critics express concerns about the potential effect of the foundation's allocation of funds on the diversity of research topics and perspectives within the Danish scientific community, as it tends to prioritize projects that align with its strategic goals. The Novo Nordisk Foundation has faced criticism for

650-527: The research landscape. The substantial grants from the foundation may inadvertently overshadow other sources of research funding and potentially lead to a concentration of resources in certain research areas closely aligned with the foundation's priorities and interests. Arguments and debates put forth by skeptics are that the foundation's focus on specific research areas, such as biomedicine and health sciences, could potentially divert attention and resources away from other equally significant disciplines that have

676-466: The sciences through awards such as the Hagedorn Prize and various scholarships and grants to support upcoming scientists and educators. The level of research funding concentration granted from enterprise foundations has consistently been a central issue in science policy discussions. Intensive concentration has been viewed both as a means to enhance and direct research investments effectively and as

#443556